BMO Capital Maintains Outperform on AMN Healthcare Services, Raises Price Target to $43
BMO Capital analyst Jeffrey Silber maintains AMN Healthcare Services (NYSE:AMN) with a Outperform and raises the price target from $40 to $43.
Stocks · News reference
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Doximity (NYSE:DOCS) stock increased by 65.6% to $34.22 during Thursday's after-market session. The market value of their outstanding shares is at $3.8 billion. The company's, Q1 earnings came out
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BMO Capital Maintains Outperform on AMN Healthcare Services, Raises Price Target to $40
BMO Capital analyst Jeffrey Silber maintains AMN Healthcare Services (NYSE:AMN) with a Outperform and raises the price target from $38 to $40.
Here's Why You Should Retain AMN Stock in Your Portfolio for Now
AMN Healthcare Services expects Q3 nurse and allied staffing revenues to grow 9-11% driven by strong healthcare demand and expanding Managed Services Programs (MSPs) which now represent 46% of consolidated revenues. The company is diversifying through AI-enabled platforms and recent acquisitions. However, competitive pressures, declining language services revenues, and regulatory challenges pose risks to growth.
Citizens Maintains Market Outperform on AMN Healthcare Services, Raises Price Target to $40
Citizens analyst Constantine Davides maintains AMN Healthcare Services (NYSE:AMN) with a Market Outperform and raises the price target from $36 to $40.
Ardelyx Presents Real-World Data at ASN Kidney Week 2026 for XPHOZAH
Ardelyx announced results from a real-world analysis presented at the American Society of Nephrology (ASN) Kidney Week 2026, demonstrating serum phosphate reductions in dialysis patients treated with XPHOZAH.
Robbins LLP Urges ARDX Stockholders to Contact the Firm for Information About the Securities Class Action Against Ardelyx, Inc.
A securities class action has been filed against Ardelyx, Inc. (NASDAQ: ARDX) alleging the company misled investors about its commercial performance and growth prospects for its drug products IBSRELA and XPHOZAH. The lawsuit covers purchases between January 13, 2025 and August 6, 2026. On August 6, 2026, Ardelyx reduced its full-year 2026 IBSRELA revenue guidance and withdrew long-term XPHOZAH guidance due to increased payer access barriers, causing the stock to drop 18% in one day from $4.87 to $4.00 per share.